Asepha, a rapidly expanding startup specializing in AI-driven pharmacy automation, has successfully closed a $4 million Seed funding round. This round was led by Glasswing Ventures and Core Innovation Capital, with additional participation from Panache, RedBud, and MGV, and follow-on support from Ripple Ventures and Front Row Ventures.
Founded in 2023 by Eunice Wu and Can Uncu, Asepha aims to tackle the challenges faced by understaffed pharmacies, where pharmacists often spend a significant portion of their time on manual administrative tasks. The company offers a suite of AI tools designed to streamline operations, including an OCR prescription entry agent with 96% accuracy and a call agent that automates a large portion of inbound calls. Their browser navigation agent also assists with real-time web-based tasks, enhancing workflow efficiency and precision. Validation trials indicate that pharmacists preferred Asepha’s AI solutions over human responses 71% of the time.
With the new funding, Asepha plans to expand its engineering and marketing teams, establish global partnerships, and increase its presence in the U.S. by opening a New York City office. The company has already secured several major Fortune 50 clients, highlighting its growing influence in the industry.
Eunice Wu, CEO and Co-Founder, emphasized the importance of allowing care teams to focus on patient needs by reducing manual workload. CTO and Co-Founder Can Uncu highlighted the role of AI in transforming industry workflows and ensuring responsible deployment through strategic research collaborations.
Asepha’s approach aligns with market trends, addressing the significant supply-demand gap in pharmacy labor and facilitating a smoother go-to-market strategy. The company is committed to developing AI-powered solutions that reduce administrative burdens and improve healthcare access.
